

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Pursuant to the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/774,147
Filing Date	February 6, 2004
First Named Inventor	Sung-Ho RYU et al
Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	10050-03USA

Sheet	1	of	4
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>MW</i>	C1	WU et al., Roles of phospholipid signaling in chemoattractant-induced responses, Journal of Cell Science, 2000; 113:2935-2940	
<i>MW</i>	C2	SCHMITT et al., Induction of T cell development and establishment of T cell competence from embryonic stem cells differentiated in vitro, Nature immunology, 2004; 5:410-417	
<i>MW</i>	C3	FAROOQUI et al., Phospholipase A2 and Its Role in Brain Tissue, Journal of Neurochemistry, 1997, 69:889-901	
<i>MW</i>	C4	GIJON and LESLIE, Regulation of arachidonic acid release and cytosolic phospholipase A2 activation, Journal of Leukocyte Biology, 1999; 65:330	
<i>MW</i>	C5	GRYNKIEWICZ et al., A New Generation of Ca ²⁺ Indicators with Greatly Improved Fluorescence Properties, Journal of Biological Chemistry, 1985; 260:3440-3450	
<i>MW</i>	C6	HAYASHI et al., Synthetic Hexa- and Heptapeptides that inhibit IL-8 from Binding to and Activating Human Blood Neutrophils, The Journal of Immunology, 1995; 154:814-824	
<i>MW</i>	C7	HE et al., The Synthetic Peptide Trp-Lys-tyr-Met-Val-D-Met is a potent chemotactic Agonist for Mouse Formyl Peptide Receptor, The Journal of Immunology, 2000; 165:4598-4605	
<i>MW</i>	C8	HIEMSTRA et al., Definition of Natural T Cell Antigens with Mimicry Epitopes Obtained from Dedicated Synthetic Peptide Libraries, The Journal of Immunology, 1998; 161:4078-4082	
<i>MW</i>	C9	ITOH et. al., Expression profile of Active Genes in Granulocytes, Blood, 1998; 4:1432-1441	
<i>MW</i>	C10	LISCOVITCH et al., Phospholipase D: molecular and cell biology of a novel gene family, Biochem. J., 2000; 345:401-415	

Examiner Signature	<i>[Signature]</i>	Date Considered	12/10/05
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/774,147
		Filing Date	February 6, 2004
		First Named Inventor	Sung-Ho RYU et al
		Art Unit	1653
Examiner Name	N/A		
Sheet 2 of 4	Attorney Docket Number	10050-03USA	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MW	C11	M'RABET et al., Differential fMet-Leu-Phe- and Plateletactivating Factor-induced Signaling Toward Ral Activation —, Journal of Biological Chemistry, 1999; 274:21847-21852	
MW	C12	MURTHY and MAKHLOUF, Differential Regulation of Phospholipid A2(PLA2)-dependent. Ca2+ Signaling in smooth muscle —, Journal of Biological Chemistry, 1998; 273:34519-34526	
MW	C13	PAN et al., fMet-Leu-Phe Stimulates Proinflammatory Cytokine Gene Expression in Human Peripheral Blood Monocytes: The Role of —, Journal of Immunology, 2000; 164:404-411	
MW	C14	PROSSNITZ et al., Signal Transducing Properties of the N-formyl Peptide Receptor Expressed in Undifferentiated HL60 Cells, Journal of Immunology, 1993; 151:5704-5715	
MW	C15	PURI, Phospholipase A2: Its role in ADP- and thrombin-induced platelet activation mechanisms, International Journal of Biochemistry and Cell Biology, 1998; 30:1107-1122	
MW	C16	RABIN et al., Chemokine Receptor Responses on T Cells are achieved through regulation of both receptor expression and signaling, Journal of Immunology, 1999; 162:3840-3850	
MW	C17	ROBSON et al., Differential Regulation of Chemokine Production in Human Peritoneal Mesothelial Cells: IFN Controls Neutrophil —, Journal of Immunology, 2001; 167:1028-1038	
MW	C18	ARAMBURU et al., Affinity-Driven peptide selection of an NFAT Inhibitor More Selective than Cyclosporin-A, Science., 1999; 285:2129-2133	
MW	C19	BADOLATO et al., Serum Amyloid A Induces Calcium Mobilization and Chemotaxis of Human Monocytes by Activating a Pertussis Toxin —, Journal of Immunology, 1995; 155:4004-4010	
MW	C20	BAE et al., Identification of novel chemoattractant peptides for human leukocytes, Blood, 2001; 97:2854-2862	

Examiner Signature	<i>[Signature]</i>	Date Considered	12/10/05
--------------------	--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Sheet 3 of 4	Application Number	10/774,147
	Filing Date	February 6, 2004
	First Named Inventor	Sung-Ho RYU et al
	Art Unit	1653
	Examiner Name	N/A
Attorney Docket Number		10050-03USA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>ME</i>	C21	BAE et al., Trp-Lys-Tyr-Met-Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus ---, Journal of Leukocyte Biology, 1999; 65:241-248	
<i>ME</i>	C22	BAE et al., Independent Functioning of Cytosolic Phospholipase A2 Phospholipase D1 in Trp-Lys-Tyr-Met-Val-D-Met-Induced ---, Journal of Immunology, 2000; 164:4089-4096	
<i>ME</i>	C23	BAEK et al., Identification of the Peptides that stimulate the Phosphoinositide Hydrolysis in Lymphocyte Cell Lines ---, Journal of Biological Chemistry, 1996; 271:8170-8175	
<i>ME</i>	C24	BERADI et al., Basic Fibroblast Growth Factor Mediates Its Effects on Committed Myeloid Progenitors by Direct Action and Has No Effect ---, Blood, 1995; 86:2123-2129	
<i>ME</i>	C25	BOEN et al., Identification of T Cell Ligands in a Library of Peptides Covalently Attached to HLA-DR4, Journal of Immunology, 2000; 165:2040-2047	
<i>ME</i>	C26	BRILL et al., Augmentation of RANTES-Induced Extracellular Signal-Regulated Kinase Mediated Signaling and T Cell Adhesion by ---, Journal of Immunology, 2001; 166:7121-7127	
<i>ME</i>	C27	DANA et al., Essential Requirement of Cytosolic Phospholipase A2 for Activation of the Phagocyte NADPH Oxidase, Journal of Biological Chemistry, 1998; 273:441-445	
<i>ME</i>	C28	DOOLEY et al., Selective Ligands for the --- Opioid Receptors Identified from a Single Mixture Based Tetrapeptide ---, Journal of Biological Chemistry, 1998; 273:18848-18856	
<i>ME</i>	C29	ROBINSON et al., Activation of Phospholipase A2 in human neutrophils by polyunsaturated fatty acids and its role in stimulation of ---, Biochem. J., 1998; 336:611-617	
<i>ME</i>	C30	SANO et al., Human Galectin-3 is a Novel Chemoattractant for Monocytes and Macrophages, Journal of Immunology, 2000; 165:2156-2164	

Examiner Signature	<i>[Signature]</i>	Date Considered	12/10/05
---------------------------	--------------------	------------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known


Application Number	10/774,147
Filing Date	February 6, 2004
First Named Inventor	Sung-Ho RYU et al
Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	10050-03USA

Sheet 4

of 4

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
MPW	C31	SEO et al., A Peptide with Unique Receptor Specificity, Journal of Immunology, 1997; 158:1895-1901	
MPW	C32	SUGDEN and CLERK, Regulation of the ERK Subgroup of MAP Kinase Cascades Through G Protein-Coupled Receptors, Cell. Signal., 1997; 9:337-351	
MPW	C33	WILSON et al., Immunogenicity.I. Use of Peptide Libraries to Identify Epitopes that activate clonotypic CD4+ T Cells and Induce —, Journal of Immunology, 1999; 163:6424-6434	
MPW	C34	WOO et al., Leukotriene B4 Stimulates Rac-ERK Cascade to Generate Reactive Oxygen Species that Mediates Chemotaxis, Journal of Biological Chemistry, 2002; 277:8572-8578	

Examiner Signature		Date Considered	12/12/05
--------------------	-------------------------------------------------------------------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.